Endovascular Treatment for Stroke From a Blocked Basilar Artery With a Large Core Infarction
Tests a clot-removal procedure versus medical care in adults with this stroke.
Plain-language title generated from the registry record
Registry title: The Efficacy and Safety of Endovascular Therapy for Acute Ischemic Stroke Due to Large Core Infarction
Key facts
- Where
- Beijing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07333950, who can take part
Where in China
- Beijing Tiantan Hospital,Capital Medical UniversityBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Tiantan Hospital
- Trial code
- NCT07333950
- Record updated
- 12 January 2026
- Original description
This study assesses the efficacy and safety of endovascular therapy in patients with acute basilar artery occlusion with large core infarction within a multicenter, prospective, open-label, blinded endpoint, randomized controlled trialRead full original descriptionShow less
The Efficacy and Safety of Endovascular Therapy for Acute Ischemic Stroke Due to Large Core Infarction -- A Multicenter, Prospective, Open-label, Blind Endpoint, Randomized Controlled Trial
This study assesses the efficacy and safety of endovascular therapy in patients with acute basilar artery occlusion with large core infarction within a multicenter, prospective, open-label, blinded endpoint, randomized controlled trial
Inclusion: The age ranged from 18 to 80 years; Acute ischemic stroke in posterior circulation, the time from stroke onset (or finally found normal) to randomization was within 24 hours; Acute basilar artery occlusion confirmed by CTA,MRA,or DSA; Posterior circulation large core infarction:NCCT or DWI showed pc-ASPECTS≤5, or Pons-Midbrain Index (PMI)≥3; NIHSS score ≥10 before randomization; Pre-stroke mRS of 0-2; Each patient or their legal representative must provide written informed consent before enrolment.
Exclusion: Any sign of intracranial hemorrhage (except microbleeds) on brain imaging prior to randomization; Enrolled in another drug or device trial or expected to participate in another drug or device treatment trial within the following 3 months; Acute cerebral infarction occurred within 48 hours after cardio cerebral vascular intervention or major surgery (patients over 48 hours can be included in the group); History of contraindication for contrast medium (except mild rash); Refractory hypertension (defined as systolic blood pressure>220 mmHg or diastolic blood pressure>110 mmHg) that cannot be controlled by drug treatment; Known to have dementia or psychiatric disease unable to complete neurological assessment and follow-up; It is known that patients with dementia or mental illness cannot complete neurological function assessment and follow-up; Patients whose life expectancy is less than 1 year (such as patients with malignant tumor, advanced cardiopulmonary disease, etc.); Any other condition (in the opinion of the site investigator) that inappropriate to participate this study; Known hereditary or acquired bleeding tendency, lack of coagulation factors, or oral anticoagulants with INR>1.7; Blood glucose<2.7 or>22.2 mmol/L; Platelet count<50×109/L, glomerular filtration rate<30ml/min or serum creatinine ≥ 3 mg/dl; Complete cerebellar infarct with significant mass effect, or bilateral thalamic infarction as evidenced by baseline neuroimaging; Known or highly suspected chronic occlusion of basilar artery; Current pregnant or breast-feeding; CTA/MRA/DSA confirmed occlusion of anterior and posterior circulation; Central nervous system vasculitis has been diagnosed or clinically suspected.